摘要
哺乳动物细胞表达系统由于存在翻译后加工修饰(PTMs)机制,能够产生分子量大、结构复杂的蛋白,是重组药物蛋白生产的优选系统。虽然非人源化的哺乳动物细胞系的PTMs与人源化细胞类似,但仍能进行人源化细胞不存在的其他PTMs,表达药物蛋白存在免疫原性、改变药物代谢动力学等缺点。近年来,人源化的细胞系已经用于治疗重组药物蛋白的生产,此类细胞系的优点在于具备和人源细胞完全一致的PTMs,表达的蛋白活性高、疗效好。目前用于重组药物蛋白生产及临床前研究的人源细胞系主要有HEK293、HT-1080、PER.C6等。本文综述了人源化细胞用于重组药物蛋白的最新进展。
Mammalian cell expression systems are the preferred systems for pharmaceutical protein production,as these cell lines are able to produce large,complex proteins with post-translational modifications( PTMs) similar to those produced in human. However,these non-human cell lines also produce PTMs that are not expressed in humans,which may lead to increased immunogenicity and altered pharmacokinetics of these products when used in humans. In recent years,the human cell lines have been used in the recombinant pharmaceutical protein production,and the advantages of such cell lines have the same PTMs as human cells. Currently,the major human cell lines,such as HEK293,HT-1080,PER C6,etc have being used in production of recombinant pharmaceutical proteins and preclinical research. This paper reviews recent research progress of the human cells used in recombinant pharmaceutical protein.
引文
[1]Razaghi A,Owens L,Heimann K.Review of the recombinant human interferon gamma as an immunotherapeutic:Impacts of production platforms and glycosylation[J].J Biotechnol,2016,240:48-60.
[2]Fischer S,Handrick R,Otte K.The art of CHO cell engineering:Acomprehensive retrospect and future perspectives[J].Biotechnol Adv,2015,33(8):1878-1896.
[3]Datta P,Linhardt RJ,Sharfstein ST.An'omics approach towards CHO cell engineering[J].Biotechnol Bioeng,2013,110(5):1255-1271.
[4]Brooks SA.Appropriate glycosylation of recombinant proteins for human use:implications of choice of expression system[J].Mol Biotech,2004,28(3):241-255.
[5]Casademunt E,Martinelle K,Jernberg M,et al.The first recombinant human coagulation factor VIII of human origin:human cell line and manufacturing characteristics[J].Eur J Haematol,2012,89(2):165-176.
[6]Wang M,lvarez-Román MT,Chowdary P,et al.Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients:a literature review and case reports[J].Blood Coagul Fibrinolysis,2016,27(7):737-744.
[7]Toby GG,Liu T,Buyue Y,et al.Recombinant factor IX Fc fusion protein maintains full procoagulant properties and exhibits prolonged efficacy in Hemophilia B mice[J].PLo S One,2016,11(2):e0148255.
[8]da Silva EM,Strufaldi MW,Andriolo RB,et al.Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II(Hunter syndrome)[J].Cochrane Database Syst Rev,2016,2:CD008185.
[9]Elstein D,Mehta A,Hughes DA,et al.Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease[J].Am J Hematol,2015,90(7):592-597.
[10]Swiech K,de Freitas MC,Covas DT,et al.Recombinant glycoprotein production in human cell lines[J].Methods Mol Biol,2015,1258:223-240.
[11]Swiech K,Kamen A,Ansorge S,et al.Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human r FVIII[J].BMC Biotechnol,2011,11:114.
[12]Enjolras N,Perot E,Le Quellec S,et al.In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line Hu H-7[J].Haemophilia,2015,21(4):e317-e321.
[13]Estes S,Melville M.Mammalian cell line developments in speed and efficiency[J].Adv Biochem Eng Biotechnol,2014,139:11-33.
[14]Tsuruta LR,Lopes Dos Santos M,et al.Genetic analyses of Per.C6 cell clones producing a therapeutic monoclonal antibody regarding productivity and long-term stability[J].Appl Microbiol Biotechnol,2016,100(23):10031-10041.
[15]Mei B,Chen Y,Chen J,et al.Expression of human coagulation factor VIII in a human hybrid cell line,HKB11[J].Mol Biotechnol,2006,34(2):165-178.
[16]Graham FL,Smiley J,Russell WC,et al.Characteristics of a human cell line transformed by DNA from human adenovirus type 5[J].J Gen Virol,1977,36(1):59-67.
[17]Nettleship JE,Watson PJ,Rahman-Huq N,et al.Transient expression in HEK 293 cells:an alternative to E.coli for the production of secreted and intracellular mammalian proteins[J].Methods Mol Biol,2015,1258:209-222.
[18]Karengera E,Robotham A,Kelly J,et al.Altering the central carbon metabolism of HEK293 cells:Impact on recombinant glycoprotein quality[J].J Biotechnol,2017,242:73-82.
[19]Vink T,Oudshoorn-Dickmann M,Roza M,et al.A simple,robust and highly efficient transient expression system for producing antibodies[J].Methods,2014,65(1):5-10.
[20]Robert MA,Chahal PS,Audy A,et al.Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms[J].Biotechnol J,2017,doi:10.1002/biot.201600193.
[21]Halff EF,Versteeg M,Brondijk TH,et al.When less becomes more:optimization of protein expression in HEK293-EBNA1 cells using plasmid titration-a case study for NLRs[J].Protein Expr Purif,2014,99:27-34.
[22]Berkner KL.Expression of recombinant vitamin K-dependent proteins in mammalian cells:factors IX and VII[J].Methods Enzymol,1993,222:450-477.
[23]Kahn JM,Le TQ.Adoption and de-adoption of drotrecogin alfa for severe sepsis in the United States[J].J Crit Care,2016,32:114-119.
[24]Fischer K,Kulkarni R,Nolan B,et al.Recombinant factor IX Fc fusion protein in children with haemophilia B(Kids B-LONG):results from a multicentre,non-randomised phase 3 study[J].Lancet Haematol,2017,4(2):e75-e82.
[25]Iorio A,Krishnan S,Myrén KJ,et al.Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products:comparisons of efficacy and weekly factor consumption[J].J Med Econ,2017,20(4):337-344.
[26]Ducore JM,Miguelino MG,Powell JS.Alprolix(recombinant Factor IX Fc fusion protein):extended half-life product for the prophylaxis and treatment of hemophilia B[J].Expert Rev Hematol,2014,7(5):559-571.
[27]Kannicht C,Ramstrom M,Kohla G,et al.Characterisation of the post-translational modifications of a novel,human cell line-derived recombinant human factor VIII[J].Thromb Res,2013,131(1):78-88.
[28]Peters RT,Toby G,Lu Q,et al.Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein[J].J Thromb Haemost,2013,11(1):132-141.
[29]Blonde L,Jendle J,Gross J,et al.Once-weekly dulaglutide versus bedtime insulin glargine,both in combination with prandial insulin lispro,in patients with type 2 diabetes(AWARD-4):a randomised,open-label,phase 3,non-inferiority study[J].Lancet,2015,385(9982):2057-2066.
[30]Wysham C,Blevins T,Arakaki R,et al.Erratum.Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in Type 2 diabetes in a randomized controlled trial(A-WARD-1).Diabetes Care 2014;37:2159-2167[J].Diabetes Care,2015,38(7):1393-1394.
[31]Reichel C.Differences in sialic acid O-acetylation between human urinary and recombinant erythropoietins:a possible mass spectrometric marker for doping control[J].Drug Test Anal,2013,5(11-12):877-889.
[32]Shahrokh Z,Royle L,Saldova R,et al.Erythropoietin produced in a human cell line(Dynepo)has significant differences in glycosylation compared with erythropoietins produced in CHO cell lines[J].Mol Pharm,2011,8(1):286-296.
[33]Pisani A,Bruzzese D,Sabbatini M,et al.Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease:a systematic review and meta-analysis of the literature[J].Genet Med,2017,19(3):275-282.
[34]Zimran A,Elstein D,Gonzalez DE,et al.Treatment-nave Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials[J].Blood Cells Mol Dis,2018,68:153-159.
[35]Zimran A,Wang N,Ogg C,et al.Seven-year safety and efficacy with velaglucerase alfa for treatment-naive adult patients with type1 Gaucher disease[J].Am J Hematol,2015,90(7):577-583.
[36]Elstein D,Hughes D,Goker-Alpan O,et al.Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease[J].J Obstet Gynaecol Res,2014,40(4):968-975.
[37]Ben Turkia H,Gonzalez DE,Barton NW,et al.Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease[J].Am J Hematol,2013,88(3):179-184.
[38]Tekoah Y,Tzaban S,Kizhner T,et al.Glycosylation and functionality of recombinant beta-glucocerebrosidase from various production systems[J].Biosci Rep,2013,33(5):e00071.
[39]Fallaux FJ,Bout A,van der Velde I,et al.New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses[J].Hum Gene Ther,1998,9(13):1909-1917.
[40]Arnold DF,Misbah SA.Cetuximab-induced anaphylaxis and Ig Especific for galactose-alpha-1,3-galactose[J].N Engl J Med,2008,358(25):2735.
[41]Jones D,Kroos N,Anema R,et al.High-level expression of recombinant Ig G in the human cell line per.c6[J].Biotechnol Prog,2003,19(1):163-168.
[42]Nagarajan T,Marissen WE,Rupprecht CE.Monoclonal antibodies for the prevention of rabies:theory and clinical practice[J].Antibody Technol J,2014,4:1-12.
[43]Schiedner G,Hertel S,Bialek C,et al.Efficient and reproducible generation of high-expressing,stable human cell lines without need for antibiotic selection[J].BMC Biotechnol,2008,8(1):13.
[44]Cho MS,Yee H,Chan S.Establishment of a human somatic hybrid cell line for recombinant protein production[J].J Biomed Sci,2002,9(6):631-638.
[45]Biaggio RT,Abreu-Neto MS,Covas DT,et al.Serum-free suspension culturing of human cells:adaptation,growth,and cryopreservation[J].Bioprocess Biosyst Eng,2015,38(8):1495-1507.
[46]Perot E,Enjolras N,Le Quellec S,et al.Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity[J].Thromb Res,2015,135(5):1017-1024.
[47]Ghaderi D,Taylor RE,Padler-Karavani V,et al.Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins[J].Nat Biotechnol,2010,28(8):863-867.
[48]Ghaderi D,Zhang M,Hurtado-Ziola N,et al.Production platforms for biotherapeutic glycoproteins.Occurrence,impact,and challenges of non-human sialylation[J].Biotechnol Genet Eng Rev,2012,28:147-175.
[49]Coco-Martin JM,Harmsen MM.A review of therapeutic protein expression by mammalian cells[J].Bio Process Int,2008,6:28-33.
[50]Swiech K,Picano-Castro V,Covas DT.Human cells:new platform for recombinant therapeutic protein production[J].Protein Expr Purif,2012,84(1):147-153.
[51]Cho MS,Yee H,Brown C,et al.Versatile expression system for rapid and stable production of recombinant proteins[J].Biotechnol Prog,2003,19(1):229-232.
